Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
Yoshinobu Onuma, Patrick W Serruys, Josep Gomez, Bernard de Bruyne, Dariusz Dudek, Leif Thuesen, Peter Smits, Bernard Chevalier, Dougal McClean, Jacques Koolen, Stephan Windecker, Robert Whitbourn, Ian Meredith, Hector Garcia-Garcia, John A Ormiston, undefined ABSORB Cohort A and B investigators
Catheterization and Cardiovascular Interventions | Published : 2011
OBJECTIVES: The ABSORB cohort A trial using the bioresorbable everolimus-eluting scaffold (BVS revision 1.0, Abbott Vascular) demonstrated a slightly higher acute recoil with BVS than with metallic stents. To reinforce the mechanical strength of the scaffold, the new BVS scaffold (revision 1.1) with modified strut design was developed and tested in the ABSORB cohort B trial. This study sought to evaluate and compare the in vivo acute scaffold recoil of the BVS revision 1.0 in ABSORB cohort A and the BVS revision 1.1 in ABSORB cohort B with the historical recoil of the XIENCE V® everolimus-eluting metal stent (EES, SPIRIT I and II). METHODS: In the ABSORB cohort B trial, 101 patients with one..View full abstract